Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and ...

The first life science tenant at Harvard’s new Allston development is a research center that could eventually become home to ...

F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...

Some women in senior leadership positions leave their jobs or reduce their hours as a result of debilitating side effects ...

Roche, announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such ...

The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise ...

The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...